Table 1.

Demographic and clinical profile of study subjects

	HIN* (n=49)	HFC* (n=25)	p value
Age	51.7 ± 6.77	52.5 ± 5.98	0.9
Gender (M:F)	26 : 23	13 : 12	0.7
Fibrosis stage	0–2	3–4
HCV genotype	α	β
1	29	14
Non-1	6	4
HCV load (log IU/ml)
Pre-Transplant	13.57 ± 12.46	13.67 ± 12.27	0.7
HCV load (IU/ml)
Post-transplant	15.78 ± 13.68	15.75 ± 13.42	0.7
Pre-transplant CTP Score
5–6	10	6
7–9	28	12
10–15	11	7	0.6
CMV Status	γ	δ
D+R−	7 (14.3%)	4 (16%)
D−R+	7 (14.3%)	3 (12%)	0.7
D+R+	21 (42.9%)	8 (32%)
D−R−	6 (12.2%)	5 (20%)
Coexistent Alcohol	17	10	0.8
Immunosuppression
Tacrolimus		16 (64%)	0.48
Cyclosporine	32 (65.3%)	7 (24%)
Sirolimus	8 (16.3%)	3 (12%)
MMF	9 (18.4%)	12 (48%)	0.9
Myfortic	16 (32.7%)	2 (8%)
AZA	2 (4.1%)	0
Prednisone	0	5 (20%)
	12 (24.5%)
No. acute rejection	15 (30.1%)	9 (36%)	0.9
Mean cumulative solumedrol (gms)	0.18	0.15	0.8

^*HIN= Hepatic Inflammation, HFC= Hepatic Fibrosis/ cirrhosis, D=Donor, R=Recipient

α, β, γ, δ not available in 14, 7, 8, and 5 cases, respectively.